Lexaria Bioscience (LEXX) announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide rodent biodistribution study. The company said, ” Distribution of a drug once it enters the body can provide vital clues as to the understanding of that drug’s ability to bind with targeted receptor cells, avoid concentration at physical sites that might be prone to fostering adverse side effects, and increase the drug’s ultimate efficacy. Lexaria hopes to discover whether the DehydraTECH processing of semaglutide improves its biodistribution in any significant way compared to the conventional orally administered semaglutide formulation practice. The FTS will be tracked via fluorescent imaging detection to evidence how and where semaglutide distributes and localizes following oral ingestion by Sprague-Dawley rats. Later in the Study, the animals will be euthanized and various key tissues will be examined including the brain, pancreas, lung, kidney, liver and heart. These tissues will be subject to more detailed fluorescent imaging detection exams which should show very specific tissue localization patterns and concentrations.” Two different test articles were manufactured for evaluation: FTS combined with ingredients in the proportions used within the Rybelsus orally-administered product sold designed to mimic Rybelsus performance, without DehydraTECH processing. FTS combined with patented DehydraTECH ingredients and processes to evidence potential biodistribution differences when DehydraTECH is used, compared to the Rybelsus-mimicking control FTS formulation. The Study includes use of a certain glucagon-like peptide-1 receptor that makes specific antibodies detectable through an immunofluorescence methodology. This will allow the analytical laboratory to confirm the extent of GLP-1 receptor binding of the two FTS formulations in the tissue samples taken from the animals, providing an additional detailed measure of the FTS distribution and localization patterns.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEXX:
- Lexaria Advances Human Study on Diabetes and Weight Loss Treatment
- Lexaria Bioscience provides update on ongoing human study GLP-1-H24-4
- Lexaria Bioscience Strengthens GLP-1 Drug Delivery Focus and Expands Patent Portfolio in 2024
- Lexaria CEO says FY25 R&D will ‘remain concentrated’ on GLP-1 investigations
- Lexaria Bioscience price target lowered to $7 from $10 at H.C. Wainwright